Hartwig Medical Database
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- cfDNA
- DNA
- Education
- End of Treatment
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Innovation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Re-use data
- Research
- Scientific publications
- Uncategorized
- Whole genome sequencing
- Working in the cloud
Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment
Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …
GMS and Hartwig sign MOU to advance precision medicine for cancer patients
Genomic Medicine Sweden (GMS) and Hartwig Medical Foundation (Hartwig) today signed a Memorandum of Understanding (MoU). This MoU formalises a strategic partnership …
DataNexus connects clinical and genomic data
DataNexus is a project initiated by the Netherlands Cancer Institute–Antoni van Leeuwenhoek (NKI-AvL) to improve data availability by integrating clinical …
GENAYA Extended: More Care and Research
The GENAYA project has been extended by two years. This gives researchers more time to collect genetic tumor data from …
The value of the GENAYA project for patients of the future
The GENAYA project has been extended through 2028. A total of 39 hospitals now participate in the project, which is led by …
United in Unique – every individual story is unique
On World Cancer Day, attention is drawn worldwide to the impact of this disease This year’s theme, United in Unique, highlights the fact …
New research shows a more significant role of genetic predisposition in adults with glioblastoma
A recent study published in npj Genomic Medicine shows that hereditary predisposition in adult glioblastoma patients is more common than …
Whole genome sequencing: the future of molecular diagnostics in gynecological cancer?
To mark Gynecological Oncology Awareness Month, we spoke with oncologist Eelke Gort about the role of molecular diagnostics in these …
Without structured real world data, it remains guesswork who truly benefits
The decision by the Dutch National Health Care Institute (Zorginstituut Nederland, ZiNL) to reassess the reimbursement of expensive medicines after …
Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed
Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough …
First time linking Hartwig Medical Database with the Netherlands Cancer Registry for AYA Patients
This July, the first data transfer was completed between the Netherlands Cancer Registry (NKR) and the Hartwig Medical Database for …
Clinical Trials Day and the importance of structurally recording treatment outcomes
Today, on Clinical Trials Day (May 20), we reflect on the importance of clinical research. For Hartwig, it’s a opportunity …
Blogs
How do you analyze 8,000 Tumor/Normal genomes in under two months?
It has been a long time coming: Hartwig Medical Foundation has transitioned to the GRCh38 (hg38) reference genome! For years, …
Read more
Medicines Policy must be based on real world data
The recent decision by the National Health Care Institute to re-evaluate expensive cancer medicines in real-world practice is a logical …
Read more
Cancer, a rare disease?
It may come as a surprise to many on this International Rare Disease Day (February 28), that a significant number …
Read more
The knowledge we gather with WGS can bring us a step closer to our goal to find an effective and suitable treatment for every single patient, not based on ‘one size fits all’, but adjusted to the characteristics of the patient and the tumor.